Skip to main content
SpringerLink
Log in

Vindesine

  • Chapter
Extravasation of Cytotoxic Agents

  • 92 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug dispo- sition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.

    PubMed  CAS  Google Scholar 

  2. Mateu J, Llop C: Delayed treatment of vindesine extravasation. Ann Pharmacother 28: 967–968, 1994.

    PubMed  CAS  Google Scholar 

  3. Dorr RT, Jones SE: Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285–288, 1979.

    Article  PubMed  CAS  Google Scholar 

  4. Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.

    Article  PubMed  CAS  Google Scholar 

  5. Dorr RT, Alberts DS, Woods MW: Vinca alkaloid ulceration: experimental mouse model and effects of local antidotes. Proc AACR 23: 109, 1982.

    Google Scholar 

Secondary literature

  1. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  2. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

  3. Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.

    Google Scholar 

  4. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  5. Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.

    Google Scholar 

  6. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  7. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  8. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Donislawski S, Gain M, Meyer-Jürshof A, et al: Vindesin: Behandlung von Paravasaten. In: Donislawski S, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 2: 20, 1994.

    Google Scholar 

  10. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  11. Dorr RT, Von Hoff DD: Drug monographs: vindesine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 957–966, 1994.

    Google Scholar 

  12. Summary of product characteristics Eldisin® (Austria), Eli Lilly, April 1999.

    Google Scholar 

  13. Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

    Ines Mader MD

  2. SMZ Floridsdorf, Krankenhaus und Geriatriezentrum, Vienna, Austria

    Patrizia E. Fürst-Weger Mag. pharm

  3. Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Austria

    Robert M. Mader DSc

  4. Anstaltsapotheke, Landeskrankenhaus — Universitätskliniken Innsbruck, Austria

    Elisabeth I. Semenitz MD, Mag. pharm

  5. Kaiser-Franz-Josef Hospital, Vienna, Austria

    Robert Terkola PharmD (Head of Pharmacy)

  6. Apotheke LKH-Univ.-Klinikum Graz, Austria

    Sabine M. Wassertheurer Mag. pharm.

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia E. Fürst-Weger Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Mader DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth I. Semenitz MD, Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Terkola PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine M. Wassertheurer Mag. pharm.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Vindesine. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_53

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3710-9_53

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3712-3

  • Online ISBN: 978-3-7091-3710-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation